Search

everythinglearnresearchcommunity

for

Search:↓

There's no strong link between Alopecia Areata, a hair loss condition, and fatty liver, but more research is needed.

Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.

Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.

Methotrexate is a promising and safe treatment for severe alopecia areata, with better results when combined with corticosteroids.

Alopecia areata greatly affects people's life quality, mental health, and work life.

Frontal fibrosing alopecia is a poorly understood condition with increasing cases and unclear treatment effectiveness.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

Childhood Alopecia Areata causes hair loss and requires varied treatments, with psychological support being crucial.

Hemp seed oil shows promise in treating localized alopecia areata.

A woman with an unusual pattern of hair loss was confirmed to have Frontal Fibrosing Alopecia and treated with specific medications.

Yellow dots and short vellus hairs are the most common signs of Alopecia Areata (AA), and trichoscopy can help diagnose AA and track treatment progress.

Hispanic/Latinx patients with alopecia areata often have it before age 40, with females and certain health conditions like rheumatoid arthritis more commonly affected.

The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

The study suggests that analyzing DNA can help treat hair loss, but more research is needed.

The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.

Both DPCP alone and with PRP are effective and safe for treating severe alopecia areata.

Phototherapy helps some patients with alopecia areata regrow hair, especially those with hair at treatment start and less severe forms of the condition.

Low vitamin D levels are linked to severe and active alopecia areata.

Bimatoprost and clobetasol are both effective for scalp hair loss, but bimatoprost works faster, has fewer side effects, and grows more colored hair.

New treatments for alopecia areata show promise, but standardized guidelines are needed.

A woman's hair loss was initially misdiagnosed as scarring hair loss but was actually a treatable autoimmune hair loss.

The study found that alopecia areata is strongly linked to autoimmune diseases and may indicate a genetic predisposition to such conditions.

The patient has frontal fibrosing alopecia (FFA).

The patient's hair loss is most likely due to diffuse alopecia areata.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Diphencyprone can help some children with alopecia areata regrow hair, but it often causes side effects.

Children with alopecia areata should only have thyroid screening if they have Down syndrome, a history of atopy, family history of thyroid disease, or signs of thyroid problems.

Serum granulysin levels can indicate the activity and prognosis of alopecia areata.